论文部分内容阅读
选取我院2011年1月~2013年6月收治的86例耐阿德福韦酯的慢性乙型肝炎患者,所有患者均给予口服恩替卡韦0.5mg,1次/d,连续治疗1年,观察患者治疗前后的HBV-DNA、ALT及AST水平,统计HBeAg阴转率。本组86例患者经恩替卡韦治疗后肝功能得到了显著改善,HBeAg的阴转率为77.9%,HBV-DNA、ALT及AST水平较治疗前有显著改善,差异有统计学意义(P<0.05)。对阿德福韦酯耐药的慢性乙型肝炎患者,采用恩替卡韦治疗是有效的,值得临床借鉴。
Eighty-six patients with adefovir dipivoxil-resistant chronic hepatitis B were selected from January 2011 to June 2013 in our hospital. All patients were given oral entecavir 0.5 mg once daily for 1 year. The patients were followed up Before and after treatment of HBV-DNA, ALT and AST levels, statistics HBeAg negative conversion rate. The group of 86 patients after entecavir treatment of liver function has been significantly improved, HBeAg negative conversion rate was 77.9%, HBV-DNA, ALT and AST levels were significantly improved than before treatment, the difference was statistically significant (P <0.05) . For patients with adefovir dipivoxil-resistant chronic hepatitis B, the treatment with entecavir is effective and worthy of clinical reference.